Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT05103423 is registered in ClinicalTrials.gov with Staidson (Beijing) Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT05103423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
June 24, 2021
Completion date
July 7, 2023
Enrollment
50 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa